Lupin : Vinita Gupta at the JP Morgan Healthcare Conference Jan 10 2023

J.P Morgan Healthcare

Conference

January 10th, 2023

Lupin Limited

Vinita Gupta, CEO

Safe Harbor Statement

Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-relatedforward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents obtained by competitors. Challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.

Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.

You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.

The Company does not undertake any obligation to update forward-looking statements to reflect new
information, future events, or otherwise after the date thereof.	2

Lupin Today

Global Presence

Local Leadership

Purposeful diversification (FY22)

API

10th

Largest Generic company

(by sales1)

$2.2 bn

Annual sales in

FY22

3rd

Largest in the US

(by prescriptions3)

4th

Largest Australia Gx4

6th

India Pharma Market Rank

(by sales3)

6th

South Africa Generic Rank

(by prescriptions5)

6%

US

India	34%
37%

NCE Income	Developed	Emerging
3%	Markets
Markets
	12%
	8%

$311 mn
EBITDA in
FY22(2)
	Reaching lives
20,500+ in 100+
Lupinytts	countries

1. Global ranking based on FY22 sales:
2. Excluding one time items

With Global Infrastructure

15 Manufacturing sites

7 R&D sites

Across India, the US, Netherlands, Brazil and Mexico

1. IQVIA MAT Sep-22
2. IQVIA MAT Jun-22

And Growing Sustainability

	•	GHG emissions
	•	savings >4.3 MtCO2e
	Renewable energy
8%
	utilization increased
		by 5.3 MW

5. IQVIA MAT Feb-22	3

Vision: A Pharmaceutical Company Focused on Delivering High Quality Medicines to Patients Around the World

United	Global	India	Other
Developed	Emerging
States	Region
Markets	Markets

API

Evolving portfolio and	Global operational
pipeline in Complex	efficiency and
platforms (Inhalation,	presence driving leverage
Biosimilars and	on CAPEX and R&D across
Injectables)	the platforms through
Scaled product platforms	markets with similar
in legacy oral, ophthalmic	regulatory regimes
and dermatology	(US, UK, Europe, Canada
	and Australia)

Delivering innovative	Global reach and scale
brands at above market	positions us as a partner of
Growth through organic	choice for innovative
and in-organic (licensing,	pharma companies in
partnering, and	South Africa, Brazil,
acquisitions) means, as	Mexico, Philippines and
well as strategic market	South East Asia
adjacencies	Leading Partner for Global
	Institutions on TB care

Meaningful scale achieving competitive costs to serve internal as well as external

customers and contribute meaningfully to Global Public Health

Continuous Improvement Culture Best in Class Global Quality

4

2022 Accomplishments

AcquisitionsPartnering

Material Approvals & NPLs

Compliance

Feb-22AUS:

Acquired Southern Cross Generic business in Australia

April-22India:

Acquired Anglo French Vitamin Mineral Supplement Brands in India

Nov-22US:

Acquired Sunovion Respiratory Brands Brovana and Xopenex in the US

Nov-22Brazil:

Acquired Bausch CNS and Oncology Brands in Brazil

Feb-22MENA:

Licensed Pegfilgrastim to with Axantia in MENA

April-22China:

Inked Strategic Partnership with Yabao to bring pediatric formulations to Chinese markets

Aug-22Japan:

Exclusive licensing agreement for Denosumab Biosimilar in Japan

Aug-22UK:

MHRA approval of Lutio (Tiotropium Bromide inhalation powder)

Sept-22Canada:

Health Canada approval for our Biosimilar Etanercept

Sept-22USA:

Exclusive launch of our Generic to Suprep Bowel Prep Kit in the US

Nov-22UK:

Launch of High Strength Luforbec in the UK a certified carbon neutral MDI

July-22USA:

US FDA EIR received and WL cleared at Somerset -- 2 out of 5 WL sites cleared

US FDA inspections: 5 out of 7 satisfactory outcomes

EU and Other Developed Market Agency inspections: 5 out of 5 satisfactory outcomes

Reported Net Sales, INR Mn

2022 EBITDA Focus and Delivery:

• Focused optimization of direct and indirect costs (e.g. Plant OPEX, Freight, FTS and Low margin SKUs)
• Global, cross-functional Integrated Business Planning Processes and implementation of leading-edge, predictive planning software
• Enhanced financial controls, resource allocation and optimization from R&D capital to CAPEX, long-range network planning and G&A
• Intensified focus on launch planning and execution

40,875	38,645		40,912
	36,040
Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23
	Reported EBITDA %
9.9%	7.3%	6.6%	11.4%
		5
Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23